{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:03:21Z","timestamp":1780985001859,"version":"3.54.1"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The tumor microenvironment (TME) has emerged as a central orchestrator of carcinogenesis, therapeutic resistance, and immune evasion, fundamentally reshaping the understanding of cancer as an ecosystem disease rather than a cell-autonomous genetic disorder. This review synthesizes contemporary advances in deconstructing the cellular and acellular architecture of the TME, encompassing cancer-associated fibroblasts, tumor-associated macrophages, aberrant vasculature, and a dynamically remodeled extracellular matrix. The molecular underpinnings of TME-mediated pathogenesis are critically evaluated, including metabolic reprogramming, epigenetic dysregulation, and systemic microbiome crosstalk, which collectively enforce immunosuppression and drive adaptive resistance. Building on this mechanistic framework, a new generation of therapeutic strategies designed to reprogram this malignant niche is highlighted: precision nanotechnologies for targeted and stimuli-responsive delivery; next-generation immunotherapies such as logic-gated CAR-T cells, bispecific engagers, and oncolytic viruses; metabolic and epigenetic modulators; stromal and vascular normalization approaches; and microbiome-based interventions, for instance fecal microbiota transplantation and defined bacterial consortia. Transformative tools, including patient-derived organoids, tumor-on-a-chip systems, 3D bioprinting, and artificial intelligence-powered multi-omics, are now enabling predictive modeling and personalized therapeutic forecasting. Despite persistent challenges posed by intratumoral heterogeneity, cellular plasticity, and the complexity of combination trial design, the convergence of these multidisciplinary approaches provides an unprecedented toolkit to durably reprogram the TME. Mastering this dynamic ecosystem is paramount to overcoming therapeutic roadblocks, and the strategic integration of these advances heralds a definitive paradigm shift toward TME-centric, adaptive, and personalized cancer therapy.<\/jats:p>","DOI":"10.3389\/fphar.2026.1836055","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:41:54Z","timestamp":1780983714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The tumor microenvironment: a dynamic ecosystem and therapeutic nexus in modern oncology"],"prefix":"10.3389","volume":"17","author":[{"given":"Meiqi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Graduate School, Heilongjiang Academy of Traditional Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Graduate School, Heilongjiang Academy of Traditional Chinese Medicine","place":["Harbin, China"]},{"name":"First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Heilongjiang Academy of Traditional Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e15734064390291","DOI":"10.2174\/0115734064390291251128060307","article-title":"Harnessing purines: anticancer activity and target-specific approaches","volume":"22","author":"Arora","year":"2026","journal-title":"Med. Chem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1053\/j.seminoncol.2024.09.001","article-title":"Role of neoadjuvant pembrolizumab in advanced melanoma","volume":"51","author":"Amir","year":"2024","journal-title":"Seminars Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11893","DOI":"10.3390\/ijms262411893","article-title":"Microenvironmental and molecular pathways driving dormancy escape in bone metastases","volume":"26","author":"Bakir","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13167-025-00403-w","article-title":"Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management","volume":"16","author":"Baldi","year":"2025","journal-title":"EPMA J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1200\/jco-25-00374","article-title":"Microbiome modulation for the treatment of solid neoplasms","volume":"43","author":"Barragan-Carrillo","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.32604\/or.2025.071152","article-title":"Branched-chain amino acid metabolic reprogramming and cancer: molecular mechanisms, immune regulation, and precision targeting","volume":"34","author":"Cai","year":"2025","journal-title":"Oncol. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/cancers18010151","article-title":"Targeting cancer-associated fibroblasts in prostate cancer: recent advances and therapeutic opportunities","volume":"18","author":"Chen","year":"","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"106043","DOI":"10.1016\/j.ebiom.2025.106043","article-title":"Profiling tumour-infiltrating immune cells in a large paediatric medulloblastoma cohort: a retrospective analysis","volume":"122","author":"Chen","year":"","journal-title":"EBioMedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102385","DOI":"10.1016\/j.mtbio.2025.102385","article-title":"Multifunctional nanoplatforms for tumor microenvironment remodeling: toward precision and intelligent cancer therapy","volume":"35","author":"Deng","year":"2025","journal-title":"Mater. Today Bio"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","article-title":"Microbiota-centered interventions: the next breakthrough in immuno-oncology?","volume":"11","author":"Derosa","year":"2021","journal-title":"Cancer Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"9954443","DOI":"10.1155\/2021\/9954443","article-title":"Toxicity of nanoparticles in biomedical application: Nanotoxicology","volume":"2021","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-physiol-042022-025619","article-title":"The role of the microbiome in the etiopathogenesis of Colon cancer","volume":"86","author":"El","year":"2024","journal-title":"Annu. Rev. Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41571-021-00502-3","article-title":"First clinical proof-of-concept that FMT can overcome resistance to ICIs","volume":"18","author":"Elkrief","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaeb4348","DOI":"10.1126\/sciadv.aeb4348","article-title":"Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4\/6 inhibitors","volume":"12","author":"Feng","year":"2026","journal-title":"Sci. Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"11052","DOI":"10.3390\/ijms231911052","article-title":"Metabolic reprogramming in tumor endothelial cells","volume":"23","author":"Garc\u00eda-Caballero","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12032-025-02754-w","article-title":"Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance","volume":"42","author":"Garemilla","year":"2025","journal-title":"Med. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/2159-8290.cd-24-0066","article-title":"Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity","volume":"14","author":"Glitza","year":"2024","journal-title":"Cancer Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1021\/acs.molpharmaceut.5c01263","article-title":"Targeting the cGAS-STING pathway for cancer immunotherapy: from small-molecule agonists to advanced nanomaterials","volume":"22","author":"Guo","year":"2025","journal-title":"Mol. Pharm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s40001-025-02618-z","article-title":"Dual role of miR-155 and exosomal miR-155 in tumor angiogenesis: implications for cancer progression and therapy","volume":"30","author":"Hussain","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: Cold-To-Hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s44174-024-00179-z","article-title":"Biomimetic nanoparticles for cancer therapy: a review of recent advances, applications, and bottlenecks","volume":"3","author":"Issaka","year":"2025","journal-title":"Biomed. Mater. and Devices"},{"key":"B28","doi-asserted-by":"publisher","first-page":"42006","DOI":"10.1038\/s41598-025-26157-z","article-title":"Machine learning driven multiomics analysis identifies disulfidptosis associated molecular subtypes in ovarian cancer","volume":"15","author":"Jin","year":"2025","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.37349\/etat.2024.00212","article-title":"Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment","volume":"5","author":"Jou","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"13351","DOI":"10.1007\/s00210-025-04234-4","article-title":"Metabolomics as a tool for understanding and treating triple-negative breast cancer","volume":"398","author":"Khan","year":"2025","journal-title":"Naunyn-Schmiedeberg's Archives Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1038\/s41598-023-32509-4","article-title":"DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors","volume":"13","author":"Laranjeira","year":"2023","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1367875","DOI":"10.3389\/fimmu.2024.1367875","article-title":"Endothelial cells in tumor microenvironment: insights and perspectives","volume":"15","author":"Leone","year":"2024","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1719675","DOI":"10.3389\/fimmu.2025.1719675","article-title":"Perineural invasion as a neuro-immune niche in head and neck cancer: mechanisms of immune evasion and therapeutic implications","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00262-026-04305-2","article-title":"Single-cell sequencing and network pharmacology coupled with molecular docking and experimental validation reveal the effects of YPFS on macrophages in stage I non-small cell lung cancer","volume":"75","author":"Li","year":"","journal-title":"Cancer Immunol. Immunother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70575","DOI":"10.1002\/mco2.70575","article-title":"Organoids in cancer research and regenerative medicine: current status, challenges, and future prospects","volume":"7","author":"Li","year":"","journal-title":"MedComm"},{"key":"B36","doi-asserted-by":"publisher","first-page":"117724","DOI":"10.1016\/j.bcp.2026.117724","article-title":"Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy","volume":"246","author":"Li","year":"","journal-title":"Biochem. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12885-026-15613-2","article-title":"Integrative multi-omics reveal a CD4+ T cell-derived six-gene signature linking the immune-stromal ecosystem to prognosis and immunotherapy selection in pancreatic cancer","volume":"26","author":"Liang","year":"2026","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s43188-025-00301-3","article-title":"Oxidative stress and pancreatic cancer: a dual role in tumorigenesis and drug toxicity","volume":"41","author":"Limbu","year":"2025","journal-title":"Toxicol. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41592-025-02969-9","article-title":"Bridging the dimensional gap from planar spatial transcriptomics to 3D cell atlases","volume":"23","author":"Lin","year":"2025","journal-title":"Nat. Methods"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e70454","DOI":"10.1002\/mco2.70454","article-title":"Tumor immunotherapy and microbiome: from bench-to-bedside applications","volume":"7","author":"Lin","year":"2026","journal-title":"MedComm"},{"key":"B41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","article-title":"Enhancing immunotherapy with tumour-responsive nanomaterials","volume":"22","author":"Linderman","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/mi16121343","article-title":"From spheroids to Tumor-on-a-Chip for cancer modeling and therapeutic testing","volume":"16","author":"Lipreri","year":"2025","journal-title":"Micromachines (Basel)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1703277","DOI":"10.3389\/fimmu.2025.1703277","article-title":"Fibroblast-immune crosstalk in oral squamous cell carcinoma: from tumor promotion to immune evasion","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1456030","DOI":"10.3389\/fimmu.2024.1456030","article-title":"Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00262-025-04274-y","article-title":"Non-genetically modified adoptive cell therapies for solid tumors: current landscape and future challenges","volume":"75","author":"Luo","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"107126","DOI":"10.1016\/j.phrs.2024.107126","article-title":"CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer","volume":"202","author":"Lv","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.gendis.2023.02.052","article-title":"Cancer organoids: a platform in basic and translational research","volume":"11","author":"Ma","year":"2024","journal-title":"Genes. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e009930","DOI":"10.1136\/jitc-2024-009930","article-title":"Arginase-1-specific T cells target and modulate tumor-associated macrophages","volume":"13","author":"Martinenaite","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41598-025-31128-5","article-title":"Targeting fibroblast activation protein in solid tumors via LNP-Mediated CAR-mRNA delivery promotes durable regression in murine models","volume":"16","author":"Meng","year":"2025","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.3390\/cancers17244016","article-title":"Synergistic disruption of survival and metastatic potential in esophageal adenocarcinoma cells through combined inhibition of HIF1\u03b1 and CD73","volume":"17","author":"Mersich","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41467-025-56392-x","article-title":"MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma","volume":"16","author":"Niveau","year":"2025","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","article-title":"In search of definitions: cancer-Associated fibroblasts and their markers","volume":"146","author":"Nurmik","year":"2020","journal-title":"Int. J. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1344272","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jpm16010008","article-title":"Development of a machine learning-based prognostic model using systemic inflammation markers in patients receiving nivolumab immunotherapy: a real-world cohort study","volume":"16","author":"Ozkerim","year":"2025","journal-title":"J. Pers. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"106810","DOI":"10.4254\/wjh.v17.i7.106810","article-title":"Microbiome dysbiosis and immune checkpoint inhibitors: dual targets in hepatocellular carcinoma management","volume":"17","author":"Pamungkas","year":"2025","journal-title":"World J. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e70631","DOI":"10.7759\/cureus.70631","article-title":"Harnessing epigenetic mechanisms to overcome immune evasion in cancer: the current strategies and future directions","volume":"16","author":"Panda","year":"2024","journal-title":"Cureus"},{"key":"B58","doi-asserted-by":"publisher","first-page":"102601","DOI":"10.1016\/j.ceb.2025.102601","article-title":"Cancer-associated fibroblasts: recent advances and therapeutic implications","volume":"98","author":"Paraskeva","year":"2026","journal-title":"Curr. Opin. Cell. Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.ircmb.2023.03.005","article-title":"Radiation therapy-activated nanoparticle and immunotherapy: the next milestone in oncology?","volume":"378","author":"Penninckx","year":"2023","journal-title":"Int. Rev. Cell. Mol. Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1039\/d5lc01060h","article-title":"Engineering perfusion to meet tumor biology: are vascularized tumor-on-a-chip models ready to drive therapy innovation?","volume":"26","author":"Poljak","year":"2026","journal-title":"Lab. Chip"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e007659","DOI":"10.1136\/jitc-2023-007659","article-title":"First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET","volume":"12","author":"Pouw","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cells14151136","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review","volume":"14","author":"Rauf","year":"2025","journal-title":"Cells"},{"key":"B63","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41746-025-01674-3","article-title":"Rethinking clinical trials for medical AI with dynamic deployments of adaptive systems","volume":"8","author":"Rosenthal","year":"2025","journal-title":"Npj Digit. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2512104","DOI":"10.1080\/2162402X.2025.2512104","article-title":"Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma","volume":"14","author":"Rovers","year":"2025","journal-title":"Oncoimmunology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1651270","DOI":"10.3389\/fimmu.2025.1651270","article-title":"Machine learning integration with multi-omics data constructs a robust prognostic model and identifies PTGES3 as a therapeutic target for precision oncology in lung adenocarcinoma","volume":"16","author":"Ruan","year":"2025","journal-title":"Front. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"103924","DOI":"10.1016\/j.drudis.2024.103924","article-title":"Recent advances in 3D bioprinting for cancer research: from precision models to personalized therapies","volume":"29","author":"Ruchika","year":"2024","journal-title":"Drug Discov. Today"},{"key":"B67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40487-025-00411-w","article-title":"Toward personalized treatment of urogenital cancers: the role of patient-derived organoids","volume":"14","author":"Sagliocchi","year":"2026","journal-title":"Oncol. Ther"},{"key":"B68","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10565-025-10092-w","article-title":"HypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment","volume":"41","author":"Salehi-Sangani","year":"2025","journal-title":"Cell. Biol. Toxicol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41529-022-00277-7","article-title":"Recent advances in biodegradable polymers for sustainable applications","volume":"6","author":"Samir","year":"2022","journal-title":"Npj Mater. Degrad."},{"key":"B70","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1007\/s00210-025-04884-4","article-title":"Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology","volume":"399","author":"Shaik","year":"2026","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s43556-025-00345-9","article-title":"CD39 and CD73: biological functions, diseases and therapy","volume":"6","author":"Shen","year":"","journal-title":"Mol. Biomed."},{"key":"B72","doi-asserted-by":"publisher","first-page":"118241","DOI":"10.1016\/j.bmc.2025.118241","article-title":"Oxidative complexity: the role of ROS in the tumor environment and therapeutic implications","volume":"127","author":"Shen","year":"","journal-title":"Bioorg Med. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1513654","DOI":"10.3389\/fonc.2024.1513654","article-title":"Mechanisms and technologies in cancer epigenetics","volume":"14","author":"Sherif","year":"2025","journal-title":"Front. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e70541","DOI":"10.1002\/mco2.70541","article-title":"Tumor cell plasticity in cancer: signaling pathways and pharmaceutical interventions","volume":"6","author":"Sun","year":"","journal-title":"MedComm"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.3390\/cancers17182983","article-title":"Development and validation of a centrosome amplification-related prognostic model in pancreatic cancer: multi-omics guided risk stratification and tumor microenvironment","volume":"17","author":"Sun","year":"","journal-title":"Cancers (Basel)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e15432","DOI":"10.1002\/advs.202515432","article-title":"Soft-drug-inspired MnSTF nano-adjuvant for safe and synergistic cGAS-STING activation in tumor immunotherapy","volume":"13","author":"Sun","year":"","journal-title":"Adv. Sci. (Weinh)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s43556-025-00396-y","article-title":"Tumor-associated macrophages in cancer: from mechanisms to application","volume":"6","author":"Tang","year":"2025","journal-title":"Mol. Biomed."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2612377","DOI":"10.1080\/2162402x.2025.2612377","article-title":"Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation","volume":"15","author":"Tang","year":"2026","journal-title":"Oncoimmunology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/cancers15030767","article-title":"Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment","volume":"15","author":"Valenza","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","article-title":"Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential","volume":"10","author":"Wang","year":"","journal-title":"Signal Transduct. Target. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","article-title":"Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside","volume":"16","author":"Wang","year":"","journal-title":"Nat. Commun."},{"key":"B83","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-025-02334-4","article-title":"Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semcancer.2025.12.002","article-title":"Microbiota and cancer immunotherapy: mechanisms, clinical implications, and precision therapeutics","volume":"118","author":"Wei","year":"2026","journal-title":"Semin. Cancer Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.actbio.2022.04.050","article-title":"Patient-derived tumour organoids: a bridge between cancer biology and personalised therapy","volume":"146","author":"Wu","year":"2022","journal-title":"Acta Biomater."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e192928","DOI":"10.1172\/JCI192928","article-title":"Targeting Pim2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells","volume":"136","author":"Wu","year":"2026","journal-title":"J. Clin. Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1670574","DOI":"10.3389\/fonc.2025.1670574","article-title":"Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy","volume":"15","author":"Xiang","year":"2025","journal-title":"Front. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.70206","article-title":"A murine bispecific antibody efficiently redirects T cells against calr mutated stem cells in vivo","volume":"101","author":"Xiong","year":"2026","journal-title":"Am. J. Hematol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3892\/ijmm.2025.5612","article-title":"Resistance to oncolytic virotherapy: multidimensional mechanisms and therapeutic breakthroughs","volume":"56","author":"Xu","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fimmu.2025.1610466","article-title":"The role of MCT1 in tumor progression and targeted therapy: a comprehensive review","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1665239","DOI":"10.3389\/fonc.2025.1665239","article-title":"Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer","volume":"15","author":"Xu","year":"2025","journal-title":"Front. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1199173","DOI":"10.3389\/fimmu.2023.1199173","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1697008","DOI":"10.3389\/fimmu.2025.1697008","article-title":"Lactylation in cancer: mechanistic insights, tumor microenvironment, and therapeutic Horizons","volume":"16","author":"Yang","year":"","journal-title":"Front. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"111963","DOI":"10.1016\/j.cellsig.2025.111963","article-title":"Exosomal miR-382-5p prevents pre-metastatic niche formation by inhibiting GPR176\/GNAS-CXCR1\/CXCR2 axis in colorectal cancer liver metastasis","volume":"134","author":"Yang","year":"","journal-title":"Cell. Signal"},{"key":"B96","doi-asserted-by":"publisher","first-page":"105018","DOI":"10.1016\/j.critrevonc.2025.105018","article-title":"Nanotechnology - microbiota synergy in cancer immunotherapy","volume":"217","author":"Yang","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2025.11.017","article-title":"Research progress of radiotherapy combined with immunotherapy for breast cancer: mechanism exploration and clinical translation","volume":"26","author":"Yijun","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1080\/14796694.2025.2599371","article-title":"Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer","volume":"21","author":"Yoshinami","year":"2025","journal-title":"Future Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7150\/ijms.123494","article-title":"Tumor-promoting gut microbes in colorectal cancer: mechanisms and translational perspectives","volume":"23","author":"Yu","year":"2026","journal-title":"Int. J. Med. Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"156561","DOI":"10.1016\/j.cyto.2024.156561","article-title":"Cancer energy reprogramming and the immune responses","volume":"177","author":"Yuan","year":"2024","journal-title":"Cytokine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e70333","DOI":"10.1002\/iid3.70333","article-title":"The progress of ferroptosis of immune cells in the tumor microenvironment and its impact on tumorigenesis and development","volume":"14","author":"Zhan","year":"2026","journal-title":"Immun. Inflamm. Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-025-02519-z","article-title":"Lactate: elucidating its indispensable role in human health","volume":"25","author":"Zhang","year":"","journal-title":"Mol. Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","article-title":"Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy","volume":"75","author":"Zhang","year":"","journal-title":"Cancer Immunol. Immunother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"915094","DOI":"10.3389\/fimmu.2022.915094","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s12672-025-03797-1","article-title":"Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"123599","DOI":"10.1016\/j.biomaterials.2025.123599","article-title":"Cancer-associated fibroblasts regulating nanomedicine to overcome sorafenib resistance in hepatocellular carcinoma with portal vein tumor thrombus","volume":"325","author":"Zhu","year":"2026","journal-title":"Biomaterials"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1836055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:41:58Z","timestamp":1780983718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1836055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":106,"alternative-id":["10.3389\/fphar.2026.1836055"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1836055","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1836055"}}